Intellia Therapeutics, Inc.

NTLANasdaq· In Vitro & In Vivo Diagnostic Substances

Price History

Revenue

$67.7M

▲ 16.9% YoY

Net Income

-$412.7M

▲ 20.5% YoY

EPS

$-3.81

▲ 27.4% YoY

Cash

$155.5M

▼ 17.8% YoY

FY 2025 · As of 2025-12-31

Pro

10-K Year-over-Year Diff

AI-powered analysis of what changed between the last two annual reports — new risks, removed language, strategy shifts.